IBSRELA achieved 73% revenue growth in 2025, driven by a first-in-class mechanism that addresses the 77% of IBS-C patients who remain symptomatic on secretagogues. Management successfully executed a patient-first strategy for XPHOZAH, maintaining access for all appropriate patients despite the loss of Medicare Part D reimbursement. The company strengthened its intellectual property moat with a new formulation patent for IBSRELA and XPHOZAH that extends protection until 2042. Operational performance ...

Market Overview - US equity futures are lower as traders assess the potential market impact of war with Iran and await significant US economic data including GDP and core PCE [1] - The S&P and Nasdaq futures are down 0.1% after trading positively overnight, with the "Magnificent Seven" stocks showing mixed performance [3] - Bond yields have reversed and are lower, while the USD remains flat; commodities show mixed results with base metals declining and precious metals, particularly gold, rallying above $5000 [1][11] Company Earnings and Stock Movements - Akamai Technologies (AKAM) shares fell 11% after a weaker-than-expected earnings outlook [3] - Ardelyx (ARDX) dropped 6% due to a softer sales forecast for its Ibsrela drug [3] - Copart (CPRT) fell 8% after reporting operating income that missed analyst estimates [3] - Floor & Decor (FND) rose 4% after exceeding earnings expectations for the fourth quarter [3] - Grail (GRAL) tumbled 47% after its cancer detection test failed to meet primary endpoints [3] - Harmonic (HLIT) increased by 9% due to strong book-to-bill ratios indicating growth potential [3] - Newmont (NEM) dropped 4% as it expects lower gold production this year [3] - Opendoor Technologies (OPEN) surged 19% after reporting better-than-expected revenue [3] - RingCentral (RNG) rose 10% after beating expectations and providing a positive forecast [3] - Texas Roadhouse (TXRH) increased by 4% as it anticipates positive sales growth [3] - Workiva Inc. (WK) gained 12% after reporting strong fourth-quarter results and optimistic forecasts [3] Economic Data and Inflation - Core personal consumption expenditure (PCE) data is expected to show an increase, which may influence interest rate decisions and the economic outlook [4] - Bloomberg Economics anticipates core inflation to accelerate, with a month-on-month increase of 0.32% in the core PCE deflator for December, raising the annual rate to 2.9% from 2.8% [4] - Wider inflation concerns are heightened by oil prices nearing a six-month high amid geopolitical tensions [5][6] Geopolitical Impact - The US military is deploying forces in the Middle East, with President Trump warning Iran of a limited strike if negotiations do not progress [6][35] - Geopolitical tensions have led to a cautious market sentiment, impacting stock performance and investor behavior [6][39]

以下文章来源于中新经纬 ，作者林琬斯 中新经纬 . 中新经纬是由中国新闻社主办的财经新媒体，拥有中国互联网新闻信息采编发布服务资质。以手机客户 端（APP）等为主要传播平台，以"权威、前瞻、专业、亲和"为特色宗旨，传播财经资讯、解读经济政 策、讲述商界故事，打造精英的财经资讯平台。 北京的小柏（化名）喜欢闻香，家里摆满了香水、香囊、香薰、线香。此前工作压力大，小柏在社 交平台上看到有博主推荐合香珠手串，便花近 200元买了一串柠檬虎眼石合香珠串。"手串的味道 靠近才能闻到，香茅、丁香、檀香的香气能让我情绪舒缓，可以安神助眠。" 近 年来 ， 合香珠 手串成为年轻人的养生新宠 。春节前后，不少消费者购买合香珠手串作为年货 送礼 。 中新经纬了解到， 有工作室 一个半小时售出价值 超 16万元的香牌、合香珠 等产品，有 线下 非遗手作 工坊 多场满员，甚至需要加场。 01 有消费 者 "对症购串" "200元一串的合香珠手串可以放在床边、办公室，既能盘，又能闻，还能戴。手串已经被我盘了 一个多月，气味有些消散，但仅作为配饰也很好看。"小柏表示。 此前，小柏还曾 "对症购串" ，在状态低迷时购入含有当归、玫瑰、灵芝 ...

TEL AVIV, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that Company management will participate in upcoming investor conferences in February and March. Oppenheimer 36th Annual Healthcare Life Sciences Conference Date and time: February 25, 2026, 1:20 p.m. ETLocation: Virtual (register here: https://event.summitcast.com/view/CTtthLh2Bi2D9 ...

Core Insights - The article discusses the background and achievements of Brendan, highlighting his academic and professional journey in the pharmaceutical and biotechnology sectors. Group 1: Academic Background - Brendan completed a Ph.D. at Stanford University in organic synthesis in 2009 [1] Group 2: Professional Experience - He worked for Merck, a major pharmaceutical company, from 2009 to 2013 [1] - Brendan has experience in biotech, including startups such as Theravance and Aspira, before joining Caltech [1] - He was the first employee and co-founder of 1200 Pharma, which spun out of Caltech and secured significant investment in the eight figures [1] Group 3: Investment Focus - Brendan remains an avid investor, concentrating on market trends, particularly in biotechnology stocks [1]

Group 1 - Novo Nordisk has nominated Jan van de Winkel and Ramona Sequeira to its board of directors, marking the first additions since a significant management shake-up in 2025 [1] - The company replaced its CEO and overhauled the board, appointing Lars Rebien Sorensen as board chairman, who also chairs the Novo Nordisk Foundation, consolidating power in a dual role [1] - Jan van de Winkel is the co-founder and CEO of Genmab, while Ramona Sequeira previously served as President of the Global Portfolio Division at Takeda Pharmaceutical Company Limited from 2022 to 2025 [1]

Core Insights - Fennec Pharmaceuticals has presented new real-world data supporting the use of PEDMARK (sodium thiosulfate injection) in adults with head and neck cancers, indicating its safe administration at least six hours after cisplatin treatment without compromising the drug's antitumor efficacy [1][2][5] - The findings highlight the potential of PEDMARK to mitigate cisplatin-induced hearing loss, a significant survivorship issue, with most high-risk patients showing no measurable hearing loss during or after treatment [1][4][5] Company Overview - Fennec Pharmaceuticals is focused on the commercialization of PEDMARK to reduce the risk of platinum-induced ototoxicity in cancer patients, having received FDA approval in September 2022 and subsequent approvals in Europe and the UK [22][24] - The company has entered into an exclusive licensing agreement with Norgine Pharmaceuticals for the commercialization of PEDMARQSI in Europe, the UK, Australia, and New Zealand [23] Industry Context - Cisplatin is widely used in treating solid tumors but is associated with a high incidence of hearing loss, affecting 60-90% of patients depending on treatment parameters [7][8] - The introduction of PEDMARK represents a significant advancement in addressing the long-term quality of life issues faced by cancer survivors due to treatment-induced hearing loss [12][9]

Core Viewpoint - Aquestive Therapeutics announced the investigational use of Anaphylm™ (dibutepinephrine) sublingual film, which achieved clinically relevant epinephrine plasma concentrations without causing a dip in diastolic blood pressure, highlighting its potential to transform anaphylaxis management [1][2]. Group 1: Product Details - Anaphylm™ is a polymer matrix-based epinephrine prodrug that is small, lightweight, and dissolves on contact, requiring no water or swallowing for administration [3]. - The product's packaging is designed to be portable and weather-resistant, making it easy to carry in a wallet or phone [3]. - If approved by the FDA, Anaphylm would be the first oral medication for the rescue treatment of severe allergic reactions, including anaphylaxis [3]. Group 2: Clinical Data and Presentations - Multiple poster presentations at the 2026 AAAAI Annual Meeting will showcase the clinical data for Anaphylm, emphasizing its differentiated profile and potential for meaningful outcomes [2]. - Key findings include the absence of a diastolic blood pressure dip following sublingual administration, which is a significant clinical concern in anaphylaxis treatment [2]. Group 3: Company Overview - Aquestive Therapeutics focuses on advancing medicines through innovative science and delivery technologies, operating as both a product developer and a Contract Development and Manufacturing Organization (CDMO) [5]. - The company has a portfolio that includes four commercialized products and a library of over 20 epinephrine prodrugs for various allergy and dermatological indications [5].

604.908.3095Forward Looking StatementsThis press release contains statements that constitute "forwardlooking information" within the meaning of applicable securities laws. Forwardlooking information is often identified by the words "may," "would," "could," "should," "will," "intend," "plan," "anticipate," "believe," "estimate," "expect" or similar expressions. Readers are cautioned that forwardlooking information is not based on historical facts but instead reflects the Company's management's expectations, ...

Core Viewpoint - Ardelyx Inc. reported a breakeven performance for Q4 2025, with sales of $125.22 million, surpassing the consensus estimate of $118.13 million [1] Revenue Performance - IBSRELA (tenapanor) revenue grew 73% in 2025 to $274.2 million, contributing to total revenues of $407.3 million; Q4 revenue for IBSRELA was $86.6 million, up 61% year over year [2] - XPHOZAH (tenapanor) revenue in 2025 was $103.6 million, with Q4 revenue of $27.8 million; expected 2026 revenue for XPHOZAH is projected between $110 million and $120 million [4] Growth Expectations - Ardelyx anticipates full-year 2026 revenue for IBSRELA to be between $410 million and $430 million, indicating at least 50% growth compared to 2025 [2] - The company expects IBSRELA to achieve $1 billion in annual revenue by 2029, with further growth anticipated thereafter [3] Pipeline Developments - Ardelyx plans to submit a Supplemental New Drug Application to the FDA for the CIC indication, pending Phase 3 trial outcomes; enrollment in the ACCEL trial is expected to complete by the end of 2026 [5] - A development program for RDX10531, a next-generation sodium/hydrogen exchanger 3 (NHE3) inhibitor, is underway, with an Investigational New Drug submission planned for the second half of 2026 [6] Technical Analysis - Ardelyx shares are currently trading 17.6% below the 20-day simple moving average (SMA) and just 0.1% below the 100-day SMA, indicating short-term weakness [7] - The stock has increased 17.83% over the past 12 months and is closer to its 52-week highs than lows [7] Analyst Consensus - The stock carries a Buy Rating with an average price target of $12.86; recent analyst actions include maintaining a Buy rating with a target of $17.00 and raising the target to $19.00 [10]